# Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin

Study · id `cardio:ct-nct03021187` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03021187](<https://clinicaltrials.gov/study/NCT03021187>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03021187

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 731 participants.

## Technical summary

Registry record NCT03021187. Randomized; double masking; primary purpose treatment. Start 2017-02-02 (actual); primary completion 2018-01-18 (actual). Results posted on 2019-11-07.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 731 participants (enrolled count; ClinicalTrials.gov record NCT03021187, source copy `cardio:ctgov-nct03021187-2020-03-02`, retrieved 2026-10-26)
- Started: 2017-02-02 (actual) (ClinicalTrials.gov record NCT03021187, source copy `cardio:ctgov-nct03021187-2020-03-02`, retrieved 2026-10-26)
- Primary completion: 2018-01-18 (actual) (ClinicalTrials.gov record NCT03021187, source copy `cardio:ctgov-nct03021187-2020-03-02`, retrieved 2026-10-26)
- Completion: 2018-08-22 (actual) (ClinicalTrials.gov record NCT03021187, source copy `cardio:ctgov-nct03021187-2020-03-02`, retrieved 2026-10-26)
- Results first posted: 2019-11-07 (ClinicalTrials.gov record NCT03021187, source copy `cardio:ctgov-nct03021187-2020-03-02`, retrieved 2026-10-26)
- Countries: United States; Canada; France; Greece; India; Japan; Mexico; Poland; Puerto Rico; Russia (ClinicalTrials.gov record NCT03021187, source copy `cardio:ctgov-nct03021187-2020-03-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03021187-2020-03-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
- Acronym: PIONEER 8
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): semaglutide
- Intervention (Drug): semaglutide
- Intervention (Drug): semaglutide
- Intervention (Drug): placebo
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial (`cardio:pubmed-31530667`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0df47ca2450abdcef30f1b0cbec06c1aa24cd25066c8159422ac32456d78674d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
